

**Supplementary figure 1.**


Four CpG sites of LINE-1 analyzed in bisulfite-converted DNA

CpG 1                  CpG 2   CpG 3                          CpG 4  
me                          me    me    me  
|                                  |    |    |  
Antisense 5' CTCGTGGTGCGCCGTTTCTTAAGCCGG 3'

Antisense-bisulfite converted 3' TTCGTGGTGCGTCGTTTTTTAAGTCGG 5'

### Supplementary figure 2.


The differences of LINE-1 methylation level (%) between frozen and FFPE tissues were observed at CpG3 and CpG4 ( $p < 0.001$ ,  $p < 0.001$ , respectively).



### Supplementary figure 3.

The average LINE-1 methylation levels at CpG1 and CpG4 together were significantly hypomethylated in the presence of venous invasion in frozen tissues, FFPE tissues and combined ( $p = 0.018$ ,  $p = 0.038$ ,  $p = 0.002$ , respectively).

\* $p < 0.05$  (unpaired  $t$  test).



**Table S1. Clinicopathological characteristics of patients with GC in frozen tissue set in this study**

<b>Characteristic</b>	<b>Gastric cancer (n=41)</b>	<b>Percentage</b>
<b>Gender</b>		
Male	30	73.17%
Female	11	26.83%
<b>Age, years</b>		
≤ 61	18	43.90%
> 61	23	56.10%
<b>T classification</b>		
T1	0	0.00%
T2	14	34.15%
T3	20	48.78%
T4	7	17.07%
<b>N classification</b>		
N0	15	36.59%
N1	7	17.07%
N2	8	19.51%
N3	11	26.83%
<b>Distance metastasis</b>		
Absent	39	95.12%
Present	2	4.88%
<b>TNM stage</b>		
I	0	0.00%
II	26	63.41%
III	13	31.71%
IV	2	4.88%
<b>Lauren Classification</b>		
Intestinal	20	48.78%
Diffuse	12	29.27%
Mixed	1	2.44%
Unknown	8	19.51%
<b>WHO classification</b>		
Differentiated	18	43.90%
Undifferentiated	20	48.78%
Unknown	3	7.32%
<b>Tumor location</b>		
Upper	11	26.83%
Middle	8	19.51%
Lower	21	51.22%
Entire	1	2.44%

---

<b>Lymphatic invasion</b>		
Identified	11	26.83%
Present, mural, peritumoral	11	26.83%
Unknown	19	46.34%
<b>Venous invasion</b>		
Identified	18	43.90%
Present, mural, peritumoral	4	9.76%
Unknown	19	46.34%
<b>Perineural invasion</b>		
Identified	16	39.02%
Present, mural, peritumoral	6	14.63%
Unknown	19	46.34%

---

**Table S2. Clinicopathological characteristics of patients with GC in FFPE tissue set in this study**

<b>Characteristic</b>	<b>Gastric cancer (n=25)</b>	<b>Percentage</b>
<b>Gender</b>		
Male	12	48.00%
Female	13	52.00%
<b>Age, years</b>		
≤ 57	14	56.00%
> 57	11	44.00%
<b>T classification</b>		
T1	12	48.00%
T2	0	0.00%
T3	1	4.00%
T4	12	48.00%
<b>N classification</b>		
N0	13	52.00%
N1	0	0.00%
N2	0	0.00%
N3	12	48.00%
<b>Distance metastasis</b>		
Absent	23	92.00%
Present	2	8.00%
<b>TNM stage</b>		
I	0	0.00%
II	23	92.00%
III	0	0.00%
IV	2	8.00%
<b>Lauren Classification</b>		
Intestinal	8	32.00%
Diffuse	15	60.00%
Mixed	1	4.00%
Unknown	1	4.00%
<b>WHO classification</b>		
Differentiated	6	24.00%
Undifferentiated	15	60.00%
Unknown	4	16.00%
<b>Tumor location</b>		
Upper	5	20.00%
Middle	5	20.00%
Lower	15	60.00%
Entire	0	0.00%

---

<b>Lymphatic invasion</b>		
Identified	11	44.00%
Present, mural, peritumoral	14	56.00%
Unknown	0	0.00%
<b>Venous invasion</b>		
Identified	22	88.00%
Present, mural, peritumoral	3	12.00%
Unknown	0	0.00%
<b>Perineural invasion</b>		
Identified	12	48.00%
Present, mural, peritumoral	13	52.00%
Unknown	0	0.00%

---

**Table S3. Primers for LINE-1 methylation analysis**

<b>LINE-1 methylation analysis</b>	<b>Forward primer (5' → 3')</b>
Forward primer for PCR (5' → 3')	TTTTGAGTTAGGTGTGGGATATA
Reverse primer for PCR (5' → 3')	Biotin-AAAATCAAAAAATTCCTTTC
Sequencing primer (5' → 3')	AGTTAGGTGTGGGATATAGT